- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT00188981
Dutch Prediction of Psychosis Study
The Dutch Prediction of Psychosis Study (DUPS) is a prospective study of predictors of the transition to psychosis in help-seeking adolescents at high risk for developing a first psychotic episode. The aim of the project is supplemented by a systematic account of the pathways to care, the disabilities and needs and the therapeutic interventions that are currently used in this population.
Multi-level assessment includes behavioral and cognitive variables as well as structural brain imaging and neurophysiological data. Subjects will be followed up at regular intervals during (at least) two years to monitor the development of their (psychotic) symptoms. This will allow us to analyze the predictive validity of the variables.
Studieoversikt
Status
Forhold
Detaljert beskrivelse
The Dutch Prediction of Psychosis Study (DUPS) is a collaboration of the Academic Medical Center in Amsterdam (AMC) and the University Medical Center in Utrecht (UMC). The main objectives are:
- Pathways to care: the description of the ways subjects at risk for psychosis get access to the health care system and the detection of obstacles to adequate treatment
- Prediction: the systematic multi-level assessment of predictors of the transition to a first psychotic episode in subjects at risk for psychosis
- Disability: the description of disabilities, deficits and needs in prodromal individuals
- Intervention: the description of the therapeutic and preventive interventions applied to prodromal individuals
While the same fundamental principles (e.g. inclusion criteria) are applied in both centers, additional instruments or paradigms are added in the separate centers according to specific interests, expertise and setting.
Our specific interest is in the social cognition and social functioning of prepsychotic individuals. Therefore, in addition to the subjects that are at high risk for psychosis according to the DUPS inclusion/exclusion criteria we are including another group of subjects that is at elevated risk for psychosis, namely subjects who have a Multiple Complex Developmental Disorder (MCDD) which is a subtype of the pervasive developmental disorders.
The study is a prospective longitudinal field-study with repeated measures to monitor subjects at high risk for psychosis.
The study sample in the UMC consists of adolescents who are already referred to adolescent psychiatric outpatient's clinics because of mental problems. After informed consent they are screened for the following inclusion and exclusion criteria:
- Age between 12 and 18 years
- No previous psychotic episode for more than one week
- Verbal IQ above 75
- Symptoms are not due to an organic mental disorder or substance abuse
Belong to one or more of the following groups:
- Basic symptoms: presence of self-perceived cognitive thought disturbances
- Familial risk plus reduced functioning: having a first- or second degree relative with a history of any psychotic disorder in combination with a deterioration of mental state and/or social functioning in the last year
- Attenuated psychotic symptoms: presence of psychotic symptoms at sub-clinical level
- Brief, limited or intermittent psychotic symptoms: having a history of psychotic symptoms with a duration of less than one week and spontaneous remission
- Multiple Complex Developmental Disorder
Assessment includes:
- basic clinical assessment
- neuropsychological measures (attention, memory, executive functioning)
- social cognitive measures (facial emotion recognition, mentalizing, social attribution)
- measures of social cognition and behavior
- EEG and Event Related Potentials (including smooth pursuit eye movement, auditory mismatch negativity)
- structural MRI
Some data will be collected retrospectively upon inclusion into the study, for example symptom history and pathways to care. Outcome is assessed after 9, 18 and 24 months.
Studietype
Registrering
Kontakter og plasseringer
Studiesteder
-
-
-
Utrecht, Nederland
- University Medical Center Utrecht, department of Child and Adolescent Psychiatry
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion criteria:
Help-seeking adolescents who belong to one or more of the following groups:
- Basic symptoms: presence of self-perceived cognitive thought disturbances
- Familial risk plus reduced functioning: having a first- or second degree relative with a history of any psychotic disorder in combination with a deterioration of mental state and/or social functioning in the last year
- Attenuated psychotic symptoms: presence of psychotic symptoms at sub-clinical level
- Brief, limited or intermittent psychotic symptoms: having a history of psychotic symptoms with a duration of less than one week and spontaneous remission
- Multiple Complex Developmental disorder
Exclusion criteria:
- A previous psychotic episode for more than one week
- Verbal IQ < 75
- Symptoms are due to an organic mental disorder or substance abuse
Studieplan
Hvordan er studiet utformet?
Designdetaljer
Samarbeidspartnere og etterforskere
Sponsor
Samarbeidspartnere
Etterforskere
- Hovedetterforsker: Patricia Schothorst, PhD, University Medical Center Utrecht, department of Child and Adolescent Psychiatry
- Hovedetterforsker: Herman van Engeland, Professor, University Medical Center Utrecht, department of Child and Adolescent Psychiatry
Studierekorddatoer
Studer hoveddatoer
Studiestart
Studiet fullført (Forventet)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- CCMOP02.0441C
- METC02/178
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .